Bayer Receives U.S. FDA Breakthrough Therapy Designation for BAY 2927088 for Non-Small Cell Lung Cancer Harboring HER2 Activating MutationsBusiness Wire • 02/26/24
Bayer Fund Awards More than $12.1M to U.S. Nonprofit Organizations in 2023, Following Latest Round of Grants Totaling $4.7MBusiness Wire • 02/21/24
Bayer slashes dividend by 95% as company faces wave of litigation over Roundup weed killerNew York Post • 02/20/24
Bayer initiates Phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosisBusiness Wire • 02/20/24
Bayer AG Enters Into Agreement With TetraScience to Ignite Innovation by Maximizing the Value of Its Scientific DataBusiness Wire • 02/05/24
Bayer shares slump after court tells firm to pay $2.25 billion over Monsanto weedkiller lawsuitMarket Watch • 01/29/24
Bayer Unveils Groundbreaking Solar Energy Projects at Sites in New Jersey and CaliforniaBusiness Wire • 01/23/24
Bayer appoints Nelson Ambrogio as new Head of Radiology Business at Pharmaceuticals DivisionBusiness Wire • 01/22/24
Bayer starts Phase II study NIRVANA to evaluate elinzanetant in women with sleep disturbances associated with menopauseBusiness Wire • 01/08/24